Rare Disease Policy in High-Income Countries: An Overview of Achievements, Challenges, and Solutions
Open Access
- 27 January 2025
- journal article
- Published by Elsevier in Value in Health
- Vol. 28 (5) , 680-685
Abstract
No abstract availableKeywords
Funding Information
- Economic and Social Research Council (2480077)
This publication has 64 references indexed in Scilit:
- Cost of Exempting Sole Orphan Drugs From Medicare NegotiationJAMA Internal Medicine, 2024
- New Reforms to Prescription Drug Pricing in the USJAMA, 2022
- RETRACTED ARTICLE: Artificial intelligence in disease diagnosis: a systematic literature review, synthesizing framework and future research agendaJournal of Ambient Intelligence and Humanized Computing, 2022
- HTA methodology and value frameworks for evaluation and policy making for cell and gene therapiesThe European Journal of Health Economics, 2020
- Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directionsPharmacoepidemiology and Drug Safety, 2020
- The burden of rare diseasesAmerican Journal of Medical Genetics Part A, 2019
- Challenges of developing and conducting clinical trials in rare disordersAmerican Journal of Medical Genetics Part A, 2017
- Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to ImpactPharmaceutical Research, 2017
- For the Sake of Justice: Should We Prioritize Rare Diseases?Health Care Analysis, 2014
- Why health equity?Health Economics, 2002